Navigation Links
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Date:9/19/2007

mg twice daily, steady-state mean trough concentrations ranged from approximately 150 -- 300 ng/ml, which are well above the EC50 (concentration required for 50% inhibition of viral replication) of RDEA806 (EC50 = 1.67 ng/ml).

Evaluation of the drug-drug interaction liability, in vitro and in vivo, demonstrated that RDEA806 is unlikely to be an inducer or inhibitor of major P450 enzymes or be affected by CYP3A4 inhibitors. When given together with ritonavir, an HIV protease inhibitor and potent inhibitor of CYP3A4, plasma levels of RDEA806 were not significantly altered. These data support preclinical data that RDEA806 may have a reduced potential for drug-drug interactions, which could ultimately lead to a safer and more convenient treatment option for patients and physicians.

"We recognize the need for new HIV drugs that demonstrate potent antiviral activity against a wide range of viral isolates, including those that are resistant to currently available NNRTIs, and that show improved safety, tolerability and reduced potential for drug-drug interactions. Yesterday's presentation of the broad spectrum of antiviral activity of RDEA806 demonstrated its in vitro activity against the majority of HIV strains carrying key reverse transcriptase mutations, including coverage of the 10 most prevalent strains of HIV found in patients failing therapy with efavirenz, marketed as Sustiva(R) by Bristol-Myers Squibb*. Based on this very favorable preclinical profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2a proof-of-concept study in HIV-infected patients, which we plan to initiate before the end of this year. The terminal half-life of up to 13 hours also gives us the opportunity to evaluate once-daily dosing in Phase 2a," said Barry D. Quart, PharmD, President and CEO.

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
(Date:12/22/2014)... , Dec. 22, 2014 NxStage Medical, ... of innovative dialysis products, announced today that the ... its System One™ to perform hemodialysis overnight while ... home nocturnal hemodialysis. NxStage,s® System One is the ... FDA for this indication. Home ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... Aug. 4 Tolerx, Inc. , a ... and cancer by modulating T cell activity, today announced ... Ph.D., as Chief Scientific Officer. Dr. de Fougerolles’ appointment ... research and early-stage product development programs involving novel therapies ...
... Healthcare, Inc. (Nasdaq: GRMH ) will host a conference ... , to discuss the company,s financial results for Q2, 2010. Management will review ... , , , ... be webcast on the investor relations section of Graymark,s website at http://www.graymarkhealthcare.com ...
Cached Medicine Technology:Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 2Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 3Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer 4Graymark Healthcare, Inc. to Host Conference Call to Discuss Q2 Financial Results 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... are encouraged to learn about Heart Failure-how to prevent it ... Failure Awareness Week February 8-14, 2009 Heart Failure Society ... Education Modules Available at www.abouthf.org ... is set for February 8-14. This is a ...
... Senior Market Sales, Inc., a leading independent marketing ... California, Inc., dba CalSurance, to offer Errors & Omissions ... open enrollment period launched Feb. 2, 2009. Insurance agents ... enroll for an 18-month policy effective March 1, 2009 ...
... all are sure that adolescents, use of cannabis causes cells ... marijuana over an extended period of time appears to greatly ... form of testicular cancer, a new study reveals. , In ... week or began to use the substance on a long-term ...
... with the holiday from fruit and wine to massage can ... The sweet delights of Valentine,s Day are thought of ... good for your heart, says a University of Michigan ... and wine, but there are components in tart cherries, grapes ...
... Medical,International Limited (NYSE: MR ), a ... today announced that it will report its,financial results ... December 31,2008, after the U.S. market closes on ... conference call at 8:00 AM on March 5, ...
... generate follow-up TRI compoundsWILMINGTON, Del., Feb. 9 ... Inc. today announced that AstraZeneca has licensed a ... for depression. Researchers at Virginia Tech ... The agreement provides AstraZeneca with a global license ...
Cached Medicine News:Health News:National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure 2Health News:National Heart Failure Awareness Week February 8-14, 2009: Visit www.abouthf.org to Learn More About Heart Failure 3Health News:Senior Market Sales Offers Discounted E&O Insurance for Agents 2Health News:Senior Market Sales Offers Discounted E&O Insurance for Agents 3Health News:Marijuana Linked to Aggressive Testicular Cancer 2Health News:Marijuana Linked to Aggressive Testicular Cancer 3Health News:Marijuana Linked to Aggressive Testicular Cancer 4Health News:Valentine's Day Indulgences Can Be Heart Healthy 2Health News:Valentine's Day Indulgences Can Be Heart Healthy 3Health News:Mindray to Report Fourth Quarter and Fiscal Year 2008 Financial Results on March 4, 2009 2Health News:AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration 2Health News:AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration 3Health News:AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration 4
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
... and high power negative lens delivering magnification ... benefit of this system is ease of ... made possible due to a superior depth ... and individual interpupillary adjustment provides stability for ...
... Left. 23 gauge thin wall ... Angled 20 degree shaft 10 mm ... set 0.5 mm behind aspiration tip. ... 46 cm (18.1 inches) of silicone ...
... pneumatic stools come with five legs for ... to 25" (total vertical travel 6"). 2" ... durable and fire retardant upholstery, available in ... by special order. Top of the range ...
Medicine Products: